Author:
Dollery Stephen J.,Zurawski Daniel V.,Bushnell Ruth V.,Tobin John K.,Wiggins Taralyn J.,MacLeod David A.,Tasker Naomi J. P. E. R.,Alamneh Yonas A.,Abu-Taleb Rania,Czintos Christine M.,Su Wanwen,Escatte Mariel G.,Meeks Heather N.,Daly Michael J.,Tobin Gregory J.
Abstract
Acinetobacter baumannii causes multi-system diseases in both nosocomial settings and a pre-disposed general population. The bacterium is not only desiccation-resistant but also notoriously resistant to multiple antibiotics and drugs of last resort including carbapenem, colistin, and sulbactam. The World Health Organization has categorized carbapenem-resistant A. baumannii at the top of its critical pathogen list in a bid to direct urgent countermeasure development. Several early-stage vaccines have shown a range of efficacies in healthy mice, but no vaccine candidates have advanced into clinical trials. Herein, we report our findings that both an ionizing γ-radiation-inactivated and a non-ionizing ultraviolet C-inactivated whole-cell vaccine candidate protects neutropenic mice from pulmonary challenge with virulent AB5075, a particularly pathogenic isolate. In addition, we demonstrate that a humoral response is sufficient for this protection via the passive immunization of neutropenic mice.
Funder
Defense Threat Reduction Agency
Subject
Immunology,Immunology and Allergy
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献